Article Sidebar

PDF
Date Published: 28/12/2022
Abstract Views: 248
Views PDF: 183
DOI: https://doi.org/10.51298/vmj.v520i1.3743
Issue
Vol. 520 No. 1A (2022)
Section
Các bài báo
How to Cite
Văn Đăng, N. ., Thị Thu Nhung, N. ., Thị Hằng, N., Văn Quảng, . L. ., & Văn Tờ, T. . (2022). EVALUATION OF THE TREATMENT RESULTS OF THE ORAL CAVITY CANCER STAGE III-IVA, B AT NATIONAL CANCER HOSPITAL. Vietnam Medical Journal, 520(1A). https://doi.org/10.51298/vmj.v520i1.3743

EVALUATION OF THE TREATMENT RESULTS OF THE ORAL CAVITY CANCER STAGE III-IVA, B AT NATIONAL CANCER HOSPITAL

Nguyễn Văn Đăng1,2,, Nguyễn Thị Thu Nhung2, Nguyễn Thị Hằng2, Lê Văn Quảng1,2, Tạ Văn Tờ2
1 Department of Oncology, Hanoi Medical University
2 Vietnam National Cancer Hospital

Main Article Content

Abstract

Objectives: oral cavity cancer patients with III-IVA,B stage. Materials and method: Uncontrolled clinical trials in 46 patients diagnosed with III-IVA,B stage oral cavity cancer at the Head and Neck Radiotherapy Department – National Cancer Hospital from September 2018 to June 2022. Results: The rate of complete response after treatment was 67.4%, the rate of patients with objective response accounted for 82.6%. Median follow-up was 16.58 months [4.86-38.13]. Overall survival rate at 12 months, 24 months and 36 months was 71.3%; 54.4% and 40.8%, respectively. The mean overall survival was 25.0 ±2.1 months. Recurrence and metastasis usually occur within the first 2 years after treatment. The progression-free survival rate at 12 months, 24 months and 36 months respectively was 70.8%; 55.9% and 49.7%. The mean progression-free survival time was 24.8 ± 2.3 months. The most common late complication is dry mouth, accounting for 71.7%. Conclusion: Concurrent chemoradiotherapy using VMAT technique in oral cavity cancer stage III-IVA,B achieved good results. Late complications occur at a low rate, demonstrating that VMAT has many advantages over basic radiotherapy techniques.

Article Details

Keywords

oral cavity cancer, III-IVA,B stage, concurrent chemoradiation, Volumetric Modulated Arc Therapy

References

1. Globocan (2020). v1.0, Cancer Incidence and Mortality, Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France.
2. Gupta N, Gupta R, Acharya AK, et al. (2016). Changing Trends in oral cancer - a global scenario. Nepal J Epidemiol. 6(4), 613–619.
3. National Comprenhensive Cancer Network (NCCN) (2022), head and neck cancer.
4. Joaquín J. Cabrera-Rodríguez. (2016). The role of radiotherapy in the treatment of oral cavity cancer, Plast Aesthet Res. 3, 158-66.
5. Reema Goel, William Moore, Baran Sume, et al. (2017). Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. American Journal of Roentgenology. 209(2), 289-303
6. Peddi, P., Shi, R., Nair, B., et al. (2015). Cisplatin, cetuximab, and radiation in locally advanced head and neck squamous cell cancer: a retrospective review. Clinical Medicine Insights: Oncology, 9, CMO-S18682.
7. Ngô Xuân Qúy (2020), Nghiên cứu kết quả hóa trị bổ trợ trước phác đồ TC và tỷ lệ bộc lộ một số dấu ấn liên quan đến ung thư lưỡi giai đoạn III-IV(M0), Luận án tiến sĩ Y học, Trường Đại học Y Hà Nội, Hà Nội.
8. Strom, T. J., Trotti, A. M., Kish, J et al. (2015). Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. Oral oncology, 51(7), 704–708. https://doi.org/10.1016/ j.oraloncology.2015.04.012
9. Ou, D., Levy, A., Blanchard, P. et al. (2016). Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: does human papilloma virus play a role?. Oral oncology, 59, 50-57.